Thermo Fisher Scientific has agreed to acquire Sanofi’s sterile manufacturing site in Ridgefield, New Jersey. The Ridgefield site is a sterile fill-finish and packaging facility with more than 200 employees, who will join Thermo Fisher following the completion of the transaction. 

The move is part of a strategy by Thermo Fisher to increase its US drug-product manufacturing capacity. Thermo Fisher operates a global sterile fill–-finish manufacturing network, which currently includes US sites in Greenville, North Carolina, and Plainville, Massachusetts. 

The move expands the companies’ strategic partnership. Under the agreement, Thermo Fisher will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher says it will invest to bring additional capacity and enhanced capabilities at the site. 

The transaction is expected to be completed in the second half of 2025, subject to customary closing conditions. Upon completion of the transaction, Sanofi’s Ridgefield facility will become part of Thermo Fisher’s Pharma Services business within its Laboratory Products and Biopharma Services segment. 

Source: Thermo Fisher Scientific